drugset / Trial / NCT03587740
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Phase 2
Active not recruiting
111 enrolled
Dana-Farber Cancer Institute
Gateway for Cancer Research · collabSusan G. Komen Breast Cancer Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1)
Timeline
- Start
- 2018-08-22
- Primary completion
- 2025-03-03
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab emtansine | Other / unclassified | — | Intravenous |